Page 51 - Key Statistics News Today

Share this article Share this article ROCKLAND, Mass., Feb. 3, 2021 /PRNewswire/ -- EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the US Food and Drug Administration (FDA) has approved TEPMETKO ® (tepotinib) following Priority Review for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET) exon 14 skipping alterations. This indication is ap...

Send Pictures of neighbors singing on their balconies and applauding health workers beamed across the world from Italy, Spain, and the United Kingdom. It was April 2020, the peak of the first wave of the coronavirus pandemic. Europe was undoubtedly the hardest hit region worldwide, and currently finds itself in a second wave which in terms of new cases dwarfs the first one. The coronavirus pandemic has pushed European governments to take unprecedented steps, including strict national lockdowns,...

More travel executives get their mission-critical industry news from Skift than any other source on the planet.Tell me more It was cutting it fine, but a long-awaited UK-EU trade deal was finally agreed on Thursday in Brussels, closing the chapter on a nearly five-year-long saga that hung like a cloud of uncertainty over the travel industry. The details in the 1,500-page document have yet to be made public, but the headline so far is the new accord means there will be no tariffs on goods when t...

Share this article Share this article DUBLIN, Dec. 21, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has initiated the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for JZP-458 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients who hav...

Share: Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib With a Focus on KRAS-G12V Mutations Trial Designed to Address Significant Unmet Medical Need in These Treatment-Resistant Tumors Verastem Oncology to Seek FDA Accelerated Approval, Pending Trial Outcome Verastem, Inc. (NASDAQ:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Ph...